Could Albumin be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?-Reply

Affiliations

¹ Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands2Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Comment

Willem-Jan R Fokkink et al. JAMA Neurol. 2017.

. 2017 Jul 1;74(7):872.

doi: 10.1001/jamaneurol.2017.0566.

¹ Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands2Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

No abstract available

Comment on

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC. Fokkink WR, et al. JAMA Neurol. 2017 Feb 1;74(2):189-196. doi: 10.1001/jamaneurol.2016.4480. JAMA Neurol. 2017. PMID: 28027337
Could Albumin Be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?
Wang Y, Zhang HL. Wang Y, et al. JAMA Neurol. 2017 Jul 1;74(7):871-872. doi: 10.1001/jamaneurol.2017.0563. JAMA Neurol. 2017. PMID: 28505216 No abstract available.